MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC
Clinical trial NCT05286957 · RECRUITING
Trial details
- NCT number
- NCT05286957
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-20
- Primary completion
- 2026-06-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.